|This article relies too much on references to primary sources. (November 2013)|
|Founded||Lausanne, Switzerland (1979)|
|Founders||Dr Rolland-Yves Mauvernay|
|Key people||Dr Rolland-Yves Mauvernay President, Thierry Mauvernay, Executive Vice President,Dr Bertrand Ducrey, CEO Debiopharm S.A, Dr Cédric Sager, CEO Debio R.P. S.A|
Debiopharm Group (Debiopharm) is a global biopharmaceutical group of companies comprising Debiopharm S.A., Debio R.P. S.A. (Recherche Pharmaceutique), Debioclinic S.A. and the two financial arms Debiomanagement S.A. and Debioinnovation S.A. The group applies scientific and clinical expertise to address unmet medical needs through the in-licensing of promising biologics and small molecules, the clinical development of the same and the out-licensing for commercialiasation.
The group is family owned. The company has developed triptorelin under the brandnames Decapeptyl/Trelstar/Pamorelin for the palliative treatment of advanced prostate cancer, endometriosis, uterine fibromyomas, precocious puberty, female infertility, breast cancer and ovarian cancer, and under the brandnames Moapar/Salvacyl for the treatment of severe sexual deviations and of oxaliplatin (Eloxatin/Elplat) for the treatment of colorectal cancer.
For thirty years Debiopharm Group has established alliances with leading biotech, pharmaceutical and start-up companies as well as with academic institutions. Sanofi-Aventis, Ipsen Pharma, Novartis, Curis, MSM Protein Technologies, Mercury Therapeutics, École Polytechnique Fédérale de Lausanne (EPFL) are a few examples of Debiopharm partners.
In 1979, Dr. Rolland-Yves Mauvernay founded Debiopharm Group. In 1981, the laboratory Cytotech was created in Martigny and a few years later became Debio R.P.. The company first worked on interferon and in 1982, started to focus on triptorelin after acquiring the rights to its development from Tulane University. The first license to market triptorelin was obtained in France, in 1986. In 1989, Debiopharm in-licensed oxaliplatin from Nagoya City University. The drug was first approved in Europe, in 1996. Debioclinic S.A. was founded in 1993. In September 2004, after having occupied various locations in Lausanne, Debiopharm Group moved its headquarters to its current situation. Today, the Debiopharm Group consists of 340 employees from 18 different countries and is supported by 400 external advisers.
Debiopharm Group was founded in 1979 and is headquartered in Lausanne, Switzerland. The group consists of Debiopharm International, Debiopharm Research & Manufacturing (Recherche Pharmaceutique), Debiopharm Diagnostics, and Debiopharm Investment.
Examples of drugs currently in clinical development:
- Debio 025 - Alisporivir (out-licensed to Novartis worldwide with the exception of Japan) - being developed for the treatment of hepatitis C virus (HCV) infection
- Debio 0932 (in-licensed from Curis) - a small molecule inhibitor targeting Heat Shock Protein 90 (Hsp90) - expected to be registered for an oncology indication
- Debio 0827 (in-licensed from Pharmaleads SAS) - being developed for the treatment of chronic pain conditions.
Examples of projects in pre-clinical or earlier stages of development:
- Debio 0719 (in-licensed from Kirin Brewery Company Ltd.) - a molecule inhibitor of the lysophosphatidic acid (LPA) receptors - being developed for cancer treatment
- Debio 0617 (in-licensed from Aurigene Discovery Technologies Ltd.) is being researched for the treatment of cancer
- Debio 0930 (in-licensed from Mercury Therapeutics, Inc.) - a small molecule activator of adenosine monophosphate-activated protein kinase (AMPK) for the treatment of type 2 diabetes
- Debio 0826 (co-developed with the EPFL)- a program aimed at the identification of novel small molecules and peptides that have anti-tumoral, anti-metastatic and anti-angiogenic properties and fight cancer stem cells
- Debio 0929 (co-developed with MSM Protein Technologies - an antibody targeting a G protein-coupled receptor (GPCR) to be developed into a new oncology therapeutic drug
- 2011: Debiopharm Group heads the HR ranking of the Bilan Magazine, SME category
- 2010: Debiopharm Group was awarded the “Frost & Sullivan European Biopharmaceuticals Company of the Year Award”
- 2004: Eloxatin® was awarded the Prix Galien
Debiopharm Group has funded a chair at the École polytechnique fédérale de Lausanne (EPFL), and sponsors three scientific awards; the Debiopharm Life Sciences Award (EPFL, Lausanne, Switzerland); the JCA (Japanese Cancer Association)-Mauvernay Award and the Debiopharm / Valais Life Sciences Award in Valais, Switzerland.
Notes and references
- Crabbé R et al., An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C. Expert Opin Investig Drugs. 2009 Feb;18(2):211-20..
- Press release: Debiopharm Group starts Phase I clinical trial with Debio 0932.
- Press release: Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions.
- Press release: Debiopharm signs R&D and Commercialisation Agreement with Kirin for the development of Debio-0719 in Oncology
- Press release: Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway
- Press release: Debiopharm Group and Mercury Therapeutics, Inc. sign an exclusive license agreement for the development and commercialisation of Debio 0930 - A first-in-class, small molecule activator of AMPK for treatment of type 2 diabetes.
- Press release: Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate For Cancer Treatment.
- Press release: Debiopharm and MSM Protein Technologies sign agreement for Research and Development of Debio 0929, a Novel Oncology Biologic.
- Press release: Frost & Sullivan Confers European Biopharmaceuticals Company of the Year Award on Debiopharm Group.
- Press release: EPFL and Debiopharm take on cancer metastasis with a new Chair.
|Wikimedia Commons has media related to Debiopharm.|